TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02206984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Study: NCT00066586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: exemestane 25 mg once daily x 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo once daily x 1 year
Study: NCT04611152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSI-301
Description: Intravitreal Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal Injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Study: NCT03125564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota transplantation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Infusion of sham

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal and Mucosal Microbiota Assessment
Description: To assess the fecal and mucosal microbiota before and after Fecal Microbiota Transplantation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Fecal and Mucosal Microbiota Assessment
Description: To assess the fecal and mucosal microbiota before and after Fecal Microbiota Transplantation
Study: NCT04197882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OrienX010 Combination with Toripalimab injection
Description: OrienX010 Produced by Oriengene Biotechnology Co.,Ltd. Strength: 1.0 mL/vial. Toripalimab infusion Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package.
Study: NCT04266808

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Education Control
Description: Participants will receive education on importance of pressure relief maneuvers and physical activity and the recommended amounts of each for prevention of pressure ulcer/injury and for physical health.
Study: NCT02299726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01242917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX-354-C
Description: 200mg film-coated tablets once daily for 12 weeks + Methotrexate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo film-coated tablets twice daily for 12 weeks + methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX354-C
Description: 100mg film-coated tablets twice daily for 12 weeks + methotrexate
Study: NCT02795117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin (reference)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01658007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leukemia
Study: NCT04140396

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion
Description: Normal saline infusion at 10mL/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine infusion
Description: Lidocaine infusion at 1.0mg/kg/hr
Study: NCT01677325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herb (YiQiSanJu)
Description: Chinese herb formula:Huangqi,huanglian,yinchen,ect
Study: NCT03076762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravesical onabotulinumtoxinA injection
Description: Each vial of onabotulinumtoxinA will be diluted with 10 ml of normal saline, resulting in 10U onabotulinumtoxinA per 1.0 ml. Patients assigned for suburothelial BoNT-A injections received 20 injections in the bladder body whereas those assigned trigonal injections will receive 10 sites injections at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravesical onabotulinumtoxinA injection
Description: Each vial of onabotulinumtoxinA will be diluted with 10 ml of normal saline, resulting in 10U onabotulinumtoxinA per 1.0 ml. Patients assigned for suburothelial BoNT-A injections received 20 injections in the bladder body whereas those assigned trigonal injections will receive 10 sites injections at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone).
Study: NCT00628030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NOURISH
Description: Participants in the NOURISH intervention will have 6 weekly face-to-face parent group sessions regarding healthy eating and physical activity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wellness Group
Description: Participants in the Wellness Group will have one face-to-face group meeting and information regarding healthy eating and physical activity will be provided on a regular basis via mail.
Study: NCT01344902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hexaminolevulinate HCl
Description: 200mg hexaminolevulinate HCl capsule 6 hours before colonoscopy
Study: NCT01593631

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acid lactase
Description: capsules cotaining 3300 FCC units of acid lactase

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acid lactase
Description: capsules containing 9000 FCC of acid lactase

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lyoph. yoghurt bacteria
Description: capsules containing 2 billion lyoph. yoghurt bacteria

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acid lactase plus yoghurt bacteria
Description: Capsules containing 3300 FCC of acid lactase and 2 billion lyoph. yoghurt bacteria

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing di-calcium-phosphate
Study: NCT01165541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: mirtazapine (7.5-45mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate extended release (Quetiapine XR)
Description: Quetiapine fumarate extended release 50-400mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine fumarate extended release (Quetiapine XR)
Description: Quetiapine fumarate extended release 50-400mg/d
Study: NCT04816084

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV2 Serology
Description: Diagnostic Test: Anti-SARS-CoV2 Serology A blood sample is collected by venipuncture at Day 0. The anti-SARS-CoV2 serological status is measured by with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays (EUROBIO®)~Other: Questionnaire~Data concerning personal exposure factors are collected in a questionnaire:~* Socio-demographic factors: sex, age,~* known risk-factor for Covid-19~* Professional factors: Employment (type, work time, location), protective measures put in place to reduce the risk of contamination~* Non-professional factors: Contact with infected individuals, carrying of protective equipment and compliance with barrier measures, transport and accomodation modalities during holidays
Study: NCT01302717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LV pacing
Description: The left ventricular lead are positioned preferentially at the posterolateral or lateral venous branches of the coronary sinus.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RV pacing
Description: The right ventricular lead are positioned at the right ventricular apex.
Study: NCT01929668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Study: NCT01396863

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HDF during the first examination
Description: The patient will receive treatment with pre-dilution hemodiafiltration during the first examination.~During the second examination the patient will receive treatment with low flux hemodialysis.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HD during the first examination
Description: The patient will receive treatment with low flux hemodialysis during the first examination.~During the second examination the patient will receive treatment with pre-dilution hemodiafiltration.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment.
Study: NCT02041026

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic yoghurt
Description: The probiotic yoghurt will be prepared using lactobacillus NN20 isolated from Kimere (a traditional fermented food product) consumed in eastern part of kenya
Study: NCT01942941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko™ electrical stimulation
Description: applied to stimulate peroneal nerve and cause active muscle twitch
Study: NCT03523559

Intervention type: GENETIC
Intervention: bladder tissue of Interstitial Cystitis and normal bladder tissue
Description: Obtain the bladder tissue of Interstitial Cystitis and normal during the operation
Study: NCT03752866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portico™ Valve, Portico Delivery System(s) and Loading System(s)
Description: Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the Portico TAVI system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portico™ Valve, FlexNav Delivery System(s) and Loading System(s)
Description: Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the FlexNav Delivery and Loading Systems.
Study: NCT03917654

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1M-EPA/AS01
Description: The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2X dilution of the high dose (160 (Micro)g/mL in 0.5 mL volume) in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by GSK

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1M-EPA/AS01
Description: The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2X dilution of the high dose (160 (Micro)g/mL in 0.5 mL volume) in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by GSK

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1M-EPA/AS01
Description: The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2X dilution of the high dose (160 (Micro)g/mL in 0.5 mL volume) in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by GSK
Study: NCT00728377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Individually Tailored (IT) Exercise Intervention This intervention is designed to increase the amount of physical activity incorporated into the daily lifestyle of pregnant women, primarily through increased walking, with the ultimate goal of achieving the American College of Obstetricians and Gynecologists (ACOG) exercise goals for pregnant women. These goals are the same as the Surgeon General's Guidelines for physical activity for nonpregnant individuals (30 minutes or more or moderate activity on most days of the week).The intervention includes: 1) individually tailored print-based materials (i.e., individually-tailored reports and stage-matched manuals), 2) self-monitoring materials, and 3) goal setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heath & Wellness
Description: The comparison intervention consists of a series of informational booklets published by the American College of Obstetricians and Gynecologists on general issues related to health and wellness during pregnancy. These include alcohol and drug use during pregnancy, easing back pain, as well as the Pregnancy Fitness brochure on the safety of exercise during pregnancy. These booklets are selected to represent high-quality, standard, low-cost, self-help material currently available to the public.
Study: NCT02686346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Phase I:~Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)~Phase II:~BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m² Days 1-2-3 of Cycles 1-2-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatine
Description: max 800mg Day 2 of Cycles 1-2-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 5 g/m² Day 2 of Cycles 1-2-3
Study: NCT00829322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil 100mg once daily for 14 days, increasing to 200mg once daily for a further 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule daily for 14 days, increasing to two capsules daily for 14 days
Study: NCT02813343

Intervention type: DEVICE
Group type: OTHER
Intervention: BlueStar app
Description: BlueStar is a smart-phone enabled application that is designed to serve as a virtual coach for patients. The app sends daily evidence-based, real-time messages as well as longitudinal feedback on how to improve diabetes management. The Bluestar app has been shown to be effective at teaching patients about dietary impacts on their blood glucose levels, encouraging patients to generate higher-quality blood glucose data for enhanced self-monitoring, and to improve overall management of diabetes as represented by reductions in levels of HgbA1c. Benefits have been demonstrated in time periods as brief as three months. One US based study showed a decrease in hospitalizations and emergency department visits among participants who use the application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BlueStar app
Description: BlueStar is a smart-phone enabled application that is designed to serve as a virtual coach for patients. The app sends daily evidence-based, real-time messages as well as longitudinal feedback on how to improve diabetes management. The Bluestar app has been shown to be effective at teaching patients about dietary impacts on their blood glucose levels, encouraging patients to generate higher-quality blood glucose data for enhanced self-monitoring, and to improve overall management of diabetes as represented by reductions in levels of HgbA1c. Benefits have been demonstrated in time periods as brief as three months. One US based study showed a decrease in hospitalizations and emergency department visits among participants who use the application.
Study: NCT00003075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide
Description: Oral Fenretinide daily for 6 months with 3 days of rest every month.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo daily for 6 months with 3 days of rest every month.
Study: NCT00749463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Gum
Description: 2 mg or 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Gum
Description: 2 mg or 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
Study: NCT02959281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing caring physicians with hemodynamic variables
Description: NICAS electrodes are applied to the skin of the forearm bilaterally (similar to EKG electrodes). Conductors, attached to the electrodes, connect the patient with the measuring system.
Study: NCT02934230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation Program
Description: Strength training: This component consists of 1 set of 10 repetitions of each exercise: a. push-ups (modified to the individual's level of function as either wall push-ups, knee push-ups, or full push-ups); b. seated row (performed with an elastic resistance band); c. chest fly (performed with an elastic resistance band); d. deltoid lift (performed with an elastic resistance band); e. biceps curls (performed with an elastic resistance band); f. triceps extensions (performed with an elastic resistance band); g. chair squats; h. hamstring curls; i. standing calf raises; j. abdominal crunches (modified to be performed seated in a chair)~Aerobics: Walking for 20 minutes at moderate intensity.~Flexibility: Chest, arm, leg and truck stretches, with each stretch to be held for 20 seconds, done for 2 repetitions.
Study: NCT03883204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Initial dose: 10 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Initial dose: 2 mg.
Study: NCT01388829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: 150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot
Study: NCT00110812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 7.5 MIU injected intramuscularly; one arm uses Proleukin together with HAART of choice (protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 7.5 MIU injected intramuscularly; one arm uses Proleukin together with HAART of choice (protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors)
Study: NCT02244203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 60732
Study: NCT00621309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin, an antibiotic used to treat TB, is administered at a dose of 300 mg day x 7 days to induce CYP3A5.
Study: NCT02244203

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00621309

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sulforaphane plus rifampicin
Description: Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes. Sulforaphane is administered daily for 7 days as a broccoli sprout extract, at a dose rate of 75 mg (\~420 umoles)per day for 7 days. Rifampicin is also administered once per day at a dose rate of 300 mg/day for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sulforaphane alone
Description: Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes
Study: NCT02766634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim Hospira (US)
Description: 5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim Hospira (US)
Description: 5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: U.S.-approved Neupogen®
Description: 5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: U.S.-approved Neupogen®
Description: 5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
Study: NCT01594229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: ABT-199 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle.
Study: NCT03888651

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete quality of life assessment
Study: NCT04472234

Intervention type: OTHER
Group type: OTHER
Intervention: BPA levels
Description: BPA (Bisfenol A) in urine, blood and follicle fluid samples